Hospital
North Canyon Medical Center INC.
North Canyon Medical Center INC. was paid $3.40M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoNORTH CANYON MEDICAL CENTER INC.
GOODING, ID 83330
GOODING, ID 83330
33aNPI1609046671assigned 03/06/2008
33bProvider typeCritical Access Hospital
28Total paid$3.40M
24GClaims76,248
24DCodes billed107
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Idaho
Rank by total paid#2 of 20
Median peer was paid$348K
This provider vs. median9.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,503 | $932K | |
| 2019 | 24,428 | $1.07M | |
| 2020 | 15,141 | $686K | |
| 2021 | 5,923 | $219K | |
| 2022 | 6,270 | $193K | |
| 2023 | 4,414 | $165K | |
| 2024incomplete | 2,569 | $137K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 4,105 | 2,644 | $734K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 4,495 | 3,359 | $729K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 1,277 | 647 | $328K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.8% | 2,422 | 2,208 | $230K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.8% | 2,002 | 1,414 | $162K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.5% | 2,966 | 2,472 | $154K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 1,291 | 983 | $110K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.9% | 946 | 761 | $100K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.5% | 1,358 | 503 | $86K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.4% | 1,411 | 520 | $81K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 879 | 786 | $71K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 1,178 | 949 | $64K |
95 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 964 | $56K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.4% | 356 | $49K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 522 | $40K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 268 | $33K |
| 80053 | Comprehensive metabolic panel | <1% | 4,969 | $30K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 642 | $22K |
| 87631 | <1% | 165 | $22K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,922 | $21K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 618 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,418 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,995 | $18K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 190 | $16K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 451 | $13K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 348 | $12K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 391 | $11K |
| 83605 | <1% | 1,601 | $10K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,360 | $10K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,809 | $10K |
| 86140 | <1% | 2,232 | $8K | |
| 83880 | <1% | 630 | $7K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 68 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 109 | $7K |
| 82553 | <1% | 887 | $6K | |
| 84484 | <1% | 975 | $6K | |
| 83690 | <1% | 1,041 | $5K | |
| 80306 | <1% | 449 | $5K | |
| 81025 | <1% | 695 | $5K | |
| 81000 | <1% | 1,733 | $5K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 122 | $4K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 279 | $4K |
| 85027 | <1% | 815 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 286 | $4K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 39 | $4K |
| 82550 | <1% | 951 | $4K | |
| 73630 | <1% | 490 | $4K | |
| 87040 | <1% | 450 | $4K | |
| 80061 | Lipid panel | <1% | 432 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 35 | $3K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 102 | $3K |
| 83021 | <1% | 301 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 626 | $3K |
| 85610 | <1% | 1,285 | $3K | |
| 90461 | <1% | 346 | $3K | |
| 85730 | <1% | 766 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 489 | $2K |
| 87088 | <1% | 339 | $2K | |
| 84145 | <1% | 147 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 699 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 624 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 413 | $1K |
| 73610 | <1% | 162 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 744 | $1K |
| 82803 | <1% | 84 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $962.97 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 29 | $933.25 |
| 73030 | <1% | 107 | $805.49 | |
| J2704 | Injection, propofol, 10 mg | <1% | 46 | $716.04 |
| 85379 | <1% | 84 | $647.32 | |
| 72100 | <1% | 50 | $589.16 | |
| 36600 | <1% | 31 | $514.56 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 46 | $489.72 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $468.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $468.00 |
| 73562 | <1% | 54 | $450.02 | |
| 84439 | <1% | 79 | $416.57 | |
| 90686 | <1% | 30 | $394.05 | |
| 73110 | <1% | 37 | $350.50 | |
| 81015 | <1% | 132 | $345.76 | |
| 76942 | <1% | 13 | $315.04 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 100 | $275.72 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 152 | $258.03 |
| 86677 | <1% | 16 | $225.68 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 75 | $208.43 |
| 73130 | <1% | 26 | $191.08 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $190.15 |
| 87070 | <1% | 17 | $161.87 | |
| 83735 | <1% | 62 | $131.32 | |
| 82150 | <1% | 16 | $79.20 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 48 | $78.85 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14 | $78.03 |
| 86308 | <1% | 12 | $57.50 | |
| A4215 | Needle, sterile, any size, each | <1% | 12 | $44.92 |
| 85652 | <1% | 25 | $30.31 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 15 | $3.08 |
| 90670 | <1% | 45 | $0.41 | |
| 90647 | <1% | 40 | $0.39 | |
| 90723 | <1% | 32 | $0.28 | |
| 90680 | <1% | 31 | $0.27 | |
| 90685 | <1% | 13 | $0.13 | |
| 90633 | <1% | 14 | $0.13 | |
| 91300 | 0% | 12 | $0.00 | |
| 96376 | 0% | 12 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 69 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 13 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 424 | $-999.47 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEMOE, SARA (CONTROLLER)
| Provider | Location | Paid |
|---|---|---|
| North Canyon Medical Center, INC | Jerome, ID | $301K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.